1. Home
  2. ASMB vs SLP Comparison

ASMB vs SLP Comparison

Compare ASMB & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$26.75

Market Cap

442.9M

Sector

Health Care

ML Signal

HOLD

Logo Simulations Plus Inc.

SLP

Simulations Plus Inc.

HOLD

Current Price

$18.25

Market Cap

367.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
SLP
Founded
2005
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
442.9M
367.9M
IPO Year
2010
1996

Fundamental Metrics

Financial Performance
Metric
ASMB
SLP
Price
$26.75
$18.25
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$44.20
$24.00
AVG Volume (30 Days)
245.6K
692.5K
Earning Date
05-06-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
91.78
N/A
EPS
N/A
0.43
Revenue
N/A
$59,577,000.00
Revenue This Year
N/A
$3.80
Revenue Next Year
$638.39
$5.90
P/E Ratio
N/A
$42.37
Revenue Growth
N/A
10.52
52 Week Low
$16.90
$11.09
52 Week High
$39.71
$21.01

Technical Indicators

Market Signals
Indicator
ASMB
SLP
Relative Strength Index (RSI) 50.41 63.43
Support Level $26.18 $17.74
Resistance Level $30.68 $18.62
Average True Range (ATR) 1.46 0.15
MACD 0.01 -0.12
Stochastic Oscillator 46.08 19.44

Price Performance

Historical Comparison
ASMB
SLP

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Share on Social Networks: